Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

著者: Sara M. Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Paré, Guillermo Villacampa, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Romualdo Barroso‐Sousa, Patricia Villagrasa, Michelle K. DeMeo, Molly DiLullo, Jorge Gómez Tejeda Zañudo, Jakob Weiß, Nikhil Wagle, Ann H. Partridge, Adrienne G. Waks, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Aleix Prat, Eric P. Winer - The Lancet 2023 被引用: 165